4,249 Shares in Verona Pharma PLC American Depositary Share $VRNA Acquired by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC acquired 4,249 shares of Verona Pharma PLC American Depositary Share, valued at approximately $389,000, during the 2nd quarter.
• Shares of Verona Pharma PLC (NASDAQ:VRNA) have seen many analysts adjusting their ratings, with two analysts rating it as "Buy" and twelve issuing a "Hold" rating.
• Recent insider selling included Director Vikas Sinha selling 4,328 shares at an average price of $13.14, leading to a 4.40% decrease in his ownership of the stock.

Wealth Enhancement Advisory Services LLC bought a new position in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,249 shares of the company's stock, valued at approximately $389,000.

Several other large investors have also recently added to or reduced their stakes in VRNA. NBC Securities Inc. purchased a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter worth approximately $34,000. GAMMA Investing LLC increased its position in shares of Verona Pharma PLC American Depositary Share by 14.0% in the 1st quarter. GAMMA Investing LLC now owns 1,837 shares of the company's stock valued at $117,000 after purchasing an additional 225 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Verona Pharma PLC American Depositary Share in the 1st quarter valued at approximately $100,000. SG Americas Securities LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share in the 1st quarter valued at approximately $357,000. Finally, Mission Wealth Management LP purchased a new stake in shares of Verona Pharma PLC American Depositary Share in the 1st quarter valued at approximately $540,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on VRNA shares. Roth Capital downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. HC Wainwright reissued a "neutral" rating and issued a $107.00 price objective (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, July 14th. Cantor Fitzgerald increased their price objective on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. Jefferies Financial Group reissued a "hold" rating and issued a $107.00 price objective (down from $140.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday, July 9th. Finally, Cowen downgraded shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $109.00.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In other news, Director Vikas Sinha sold 4,328 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $56,869.92. Following the completion of the sale, the director directly owned 94,112 shares in the company, valued at $1,236,631.68. The trade was a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David R. Ebsworth sold 1,904 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $25,018.56. Following the sale, the director owned 880,499 shares of the company's stock, valued at approximately $11,569,756.86. This trade represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 540,584 shares of company stock valued at $7,103,274. Corporate insiders own 4.80% of the company's stock.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of VRNA opened at $106.95 on Wednesday. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87. The company has a 50-day simple moving average of $105.98 and a 200-day simple moving average of $88.40. Verona Pharma PLC American Depositary Share has a 52-week low of $31.09 and a 52-week high of $106.93. The company has a market capitalization of $9.22 billion, a PE ratio of -108.02 and a beta of 0.05.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. The firm had revenue of $103.14 million during the quarter, compared to the consensus estimate of $90.41 million. Equities research analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.